Cloud Zoom small image
基因改造 iPSC来源的神经干细胞LRRK2 G2019SHOM  英国axol原装   ax0310

现价: 0.00
¥0
节省
¥0
市场价格
当前销售数量: 179
折扣:0折
本单还可以继续购买
数量:

库存0

  • 产品描述
  • 产品特性
  • 评价

axolGEM iPSC-Derived Neural Stem Cells LRRK2 G2019S HOM (1.5 million cells) and Neural Plating-XF Medium (30 mL)


Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is heterozygous for the G2019S mutation where one allele contains the mutation and the other allele is wild type at the locus. Click on the product images to see the data and further details. 


The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005). 


Starting material Dermal fibroblast
Donor gender Female
Donor age at sampling 64 yrs
Karyotype Normal
Reprogramming method Episomal vector
Induction method Monolayer & chemically defined medium
Genetic modification Heterozygous for the LRRK2 G2019S mutation (GGC>AGC)
Genetic modification Contains a puromycin resistance cassette (intronic)
Size ≥1.5 million cells
Kit components 1 vial of axolGEM Neural Stem Cells (≥1.5 million cells) and 1 bottle of Plating-XF Medium (30 mL)
Growth properties Adherent
Shipping conditions Dry ice
Storage conditions Liquid nitrogen